Search Results - "Pluzanski, Adam"

Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study.

Authors: Pluzanski, Adam Bryl, Maciej Chmielewska, Izabela et al.

Source: Cancers. Mar2023, Vol. 15 Issue 5, p1581. 12p.

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

Authors: Mok, Tony S. Cheng, Ying Zhou, Xiangdong et al.

Source: Drugs. Feb2021, Vol. 81 Issue 2, p257-266.

Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study).

Authors: Janzic, Urska Maimon Rabinovich, Natalie Shalata, Walid et al.

Source: Current Oncology. Aug2024, Vol. 31 Issue 8, p4369-4381. 13p.

Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT).

Authors: Janžič, Urška Turnšek, Nina Dediu, Mircea et al.

Source: Current Oncology. Aug2022, Vol. 29 Issue 8, p5833-5845. 13p. 2 Charts, 2 Graphs.

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment.

Authors: Agbarya, Abed Shalata, Walid Addeo, Alfredo et al.

Source: Journal of Clinical Medicine. Mar2022, Vol. 11 Issue 6, p1738-N.PAG. 16p.

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.

Authors: Antonia, Scott J Borghaei, Hossein Ramalingam, Suresh S et al.

Source: Lancet Oncology. Oct2019, Vol. 20 Issue 10, p1395-1408. 14p.

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Authors: Wu, Yi-Long Cheng, Ying Zhou, Xiangdong et al.

Source: Lancet Oncology. Nov2017, Vol. 18 Issue 11, p1454-1466. 13p.

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Authors: Brahmer, Julie Reckamp, Karen L. Baas, Paul et al.

Source: New England Journal of Medicine. 7/9/2015, Vol. 373 Issue 2, p123-135. 13p.

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.

Authors: Ramalingam, Suresh S Jänne, Pasi A Mok, Tony et al.

Source: Lancet Oncology. Nov2014, Vol. 15 Issue 12, p1369-1378. 10p.

Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

Authors: Borghaei H Balli D Paz-Ares LG et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Jun 26, pp. OF1-OF14. Date of Electronic Publication: 2026 Jun 26.

Publication Type: Journal Article

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis.

Authors: Peters S Paz-Ares LG Reck M et al.

Source: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2025 Jan; Vol. 20 (1), pp. 94-108. Date of Electronic Publication: 2024 Oct 04.

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE

Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050.

Authors: Pu X Li J Zhang B et al.

Source: Future oncology (London, England) [Future Oncol] 2024; Vol. 20 (37), pp. 2971-2982. Date of Electronic Publication: 2024 Oct 03.

Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase III; Randomized Controlled Trial

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.

Authors: Reck M Ciuleanu TE Lee JS et al.

Source: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2023 Aug; Vol. 18 (8), pp. 1055-1069. Date of Electronic Publication: 2023 May 03.

Publication Type: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.

Authors: Brahmer JR Lee JS Ciuleanu TE et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Feb 20; Vol. 41 (6), pp. 1200-1212. Date of Electronic Publication: 2022 Oct 12.

Publication Type: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.

Authors: Paz-Ares LG Ciuleanu TE Pluzanski A et al.

Source: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2023 Jan; Vol. 18 (1), pp. 79-92. Date of Electronic Publication: 2022 Aug 30.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.

Authors: Paz-Ares LG Ramalingam SS Ciuleanu TE et al.

Source: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2022 Feb; Vol. 17 (2), pp. 289-308. Date of Electronic Publication: 2021 Oct 12.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

Authors: Borghaei H Gettinger S Vokes EE et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Mar 01; Vol. 39 (7), pp. 723-733. Date of Electronic Publication: 2021 Jan 15.

Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients.

Authors: Pluzanski A Krzakowski M Kowalski D et al.

Source: ESMO open [ESMO Open] 2020 Nov; Vol. 5 (6), pp. e001011.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer.

Authors: Corral J Mok TS Nakagawa K et al.

Source: Future oncology (London, England) [Future Oncol] 2019 Aug; Vol. 15 (24), pp. 2795-2805. Date of Electronic Publication: 2019 Jul 17.

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

Authors: Mok TS Cheng Y Zhou X et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2018 Aug 01; Vol. 36 (22), pp. 2244-2250. Date of Electronic Publication: 2018 Jun 04.

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE